Manufacturer VerifiedChina

Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Yiling

Yiling Pharmaceutical is a pioneering Chinese TCM and innovative pharmaceutical manufacturer headquartered in Shijiazhuang, Hebei, China, founded in 1992 by academician Wu Yiling. The company achieved annual revenue of CNY 7.831 billion in 2025, with net profit of CNY 12.86 billion and operating cash flow surging 190.75%. Yiling is globally unique for transforming its proprietary "collateral disease theory" into a fully integrated industrial pipeline spanning theory, clinical research, manufacturing, and education. The company employs over 15,000 staff including 1,399 dedicated R&D personnel, with R&D spending reaching 10.07% of revenue — matching top-tier innovative pharma companies.

Strengths: Unparalleled R&D intensity (10.07% of revenue, CNY 7.88B) exceeding most TCM peers by 3-5x; proprietary "collateral disease theory" provides unique scientific differentiation and patent protection; successful US market entry via 18 ANDA-approved generic drugs through subsidiary Yiling Wanzhou; dramatic financial turnaround in 2025 with core net profit up 254% and operating cash flow up 190.75%; 10,000+ medical institution and 300,000+ pharmacy network penetration across China; innovative drug pipeline including Phase III oncology candidate XY0206.
Weaknesses: Heavy revenue concentration in respiratory category products creates epidemiological cyclical risk; previous public controversy over flagship product efficacy claims caused reputational damage; international brand recognition remains limited outside professional medical circles; aggressive R&D spending creates margin pressure during product development cycles.

Core Business Areas

Respiratory & Anti-infective TCM Products — Core Business
• Lianhua Qingwen capsule/granule respiratory viral infections
• Lianhua Qingke cough and respiratory relief

Cardiovascular & Metabolic TCM
• Collateral-disease-theory-based cardiovascular formulations
• Diabetes and metabolic syndrome TCM interventions

Chemical Generic Pharmaceuticals Yiling Wanzhou
• 18 US ANDA-approved generic drug products
• Oncology and anti-infective synthetic APIs

Innovative Drug Pipeline
• XY0206 — Phase III for acute myeloid leukemia
• Multiple preclinical small-molecule candidates

Industry Rankings

10Top 10 Traditional Chinese Medicine Manufacturers & Suppliers

Mfr

Corporate Report

Yiling Pharmaceutical is a China-based innovative TCM and pharmaceutical manufacturer headquartered in Shijiazhuang, Hebei Province. Founded in 1992 by academician Wu Yiling, the company has uniquely transformed its proprietary "collateral disease theory" into a comprehensive industrial ecosystem — the only company worldwide to integrate academic theory, clinical validation, large-scale manufacturing, and medical education into a single enterprise. With 2025 revenue of CNY 7.831 billion and over 15,000 employees, Yiling represents the cutting edge of evidence-based TCM industrialization.

Core Business

Yiling's flagship products — Lianhua Qingwen and Lianhua Qingke — dominate the respiratory TCM category in China, supported by extensive clinical data and academic marketing. The company has successfully extended its manufacturing platform into Western chemical generics through subsidiary Yiling Wanzhou, which holds 18 US ANDA approvals. Its innovative drug pipeline includes XY0206 for acute myeloid leukemia in Phase III clinical trials. With 1,399 dedicated R&D personnel and R&D spending at 10.07% of revenue, Yiling operates at an innovation intensity matching global innovative pharma benchmarks.

Key Strengths

1. Record R&D investment of CNY 7.88 billion (10.07% of revenue) — 3-5x typical TCM industry levels. 2. Dramatic 2025 financial turnaround with core net profit surging 254% and operating cash flow jumping 190.75%. 3. Unique "collateral disease theory" IP creating sustainable competitive differentiation. 4. Successful dual-market strategy with 18 US ANDA-approved generics through Yiling Wanzhou. 5. Massive distribution network spanning 100,000+ medical institutions and 300,000+ pharmacies.

Challenges & Outlook

Revenue concentration in respiratory categories creates exposure to epidemiological cycle risk. Historical public controversy over flagship product efficacy claims has left residual reputational sensitivity in certain markets. The company must balance increasing R&D intensity with margin preservation as its innovative pipeline advances toward commercialization. VerityRank Score of 85/100 reflects industry-leading R&D commitment, strong financial recovery, and robust manufacturing infrastructure, with moderate concentration risk.

VerityRank Score

85/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

China

Founded

1992

Employees

15000

Factories

Smart manufacturing bases in Shijiazhuang and Hengshui with international CGMP-certified capsule and granule lines, plus chemical API synthesis platform (Yiling Wanzhou) with 18 US ANDA approvals.

Listing

SZSE: 002603

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website SZSE: 002603 , Yiling Pharmaceutical 2025 Annual Report, Yiling 2025 Core Net Profit Growth, Yiling Pharmaceutical Official Website, Wikipedia — Yiling Pharmaceutical

Back to Rankings